96% of Mild Tardive Dyskinesia Patients Improve Movements with Valbenazine
In a survey of 90 patients with clinician-reported mild tardive dyskinesia treated with valbenazine, 96% showed reduced uncontrolled movements, with 86% improving within four weeks. Clinicians also reported that 83% regained independence and over 90% saw functional gains in speech, dexterity, social and emotional domains.
1. Survey Design and Patient Population
The analysis drew on chart data and clinician recall for 315 tardive dyskinesia patients treated with valbenazine between January and June 2024, focusing on a subgroup of 90 individuals rated with mild movement severity. Each patient completed at least two months of treatment and had at least one follow-up evaluation.
2. Movement Improvement Outcomes
Following initiation of valbenazine, 96% of mild TD patients experienced reduced uncontrolled movements, and 86% of those responders showed improvement within four weeks of treatment start.
3. Functional and Independence Benefits
Beyond movement gains, clinicians observed functional improvements in over 90% of impacted patients across speech, dexterity, social and emotional domains. Additionally, 83% of patients regained independence, and 70% of those working or studying reported enhanced willingness or ability to engage in work or school activities.